Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
03-2024 | 03-2023 | 03-2022 | 03-2021 | 03-2020 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 635,365 | 376,532 | 493,817 | 400,146 | 100,571 |
Receivables | 5,503 | 885 | 12,861 | 1,144 | 3,045 |
TOTAL | $665,770 | $404,333 | $512,931 | $409,006 | $109,076 |
Non-Current Assets | |||||
PPE Net | 462 | 333 | 330 | 201 | 65 |
Other Non-Current Assets | 133 | 1,172 | 2,303 | 3,282 | 246 |
TOTAL | $595 | $1,505 | $2,633 | $3,483 | $311 |
Total Assets | $666,365 | $405,838 | $515,564 | $412,489 | $109,387 |
Liabilities | |||||
Current Liabilities | |||||
Accounts payable and accrued liabilities | 7,170 | 1,703 | 18,800 | 2,432 | 4,380 |
Accrued Expenses | 41,300 | 40,421 | 24,575 | 15,160 | 10,938 |
TOTAL | $48,608 | $43,297 | $44,520 | $18,771 | $15,318 |
Non-Current Liabilities | |||||
aiOther Non-Current Liabilities | 0 | 47 | 1,219 | 2,238 | 0 |
TOTAL | $N/A | $47 | $1,219 | $2,238 | $N/A |
Total Liabilities | $48,608 | $43,344 | $45,739 | $21,009 | $15,318 |
Shareholders' Equity | |||||
Shares Outstanding, K | 146,054 | 130,408 | 116,505 | 97,977 | 81,812 |
Common Shares | 14 | 13 | 12 | 10 | 5 |
Retained earnings | -825,683 | -566,347 | -355,387 | -198,657 | -91,226 |
Other shareholders' equity | 1,908 | 852 | 404 | -298 | -16 |
TOTAL | $617,757 | $362,494 | $469,825 | $391,480 | $94,069 |
Total Liabilities And Equity | $666,365 | $405,838 | $515,564 | $412,489 | $109,387 |